cytochrome P450 2C19 (cytochrome P450 2C17, cytochrome P450 11A, mephenytoin 4-hydroxylase, cytochrome P450 254C, CYP2C19)

From Aaushi
Jump to navigation Jump to search

Function

Compartment

membrane-bound, endoplasmic reticulum

Expression

highly inducible

Polymorphism

  • genetic variation in CYP2C19 is responsible for poor drug metabolism [MIM:609535]
  • individuals can be characterized as either
    • extensive metabolizers
    • poor metabolizers
      • inherited in an autosomal recessive manner
      • 2-5% of Caucasians
      • 13-23% of Asian populations
      • 38-79% of individuals from Polynesia & Micronesia.
  • several-many different alleles of CYP2C19

Laboratory

More general terms

References

  1. UniProt http://www.uniprot.org/uniprot/P33261.html
  2. Prescriber's Letter 13(3): 2006 Cytochrome P450 Drug Interactions Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=220233&pb=PRL (subscription needed) http://www.prescribersletter.com
  3. Cytochrome P450 Allele Nomenclature committee, CYP2C19 alleles http://www.cypalleles.ki.se/cyp2c19.htm
  4. Prescriber's Letter 17(1): 2010 Cytochrome P450 Drug Interactions CHART: Cytochrome P450 Drug Interactions COMMENTARY: Proton Pump Inhibitor and Plavix Interaction: An Update Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=260112&pb=PRL (subscription needed) http://www.prescribersletter.com
  5. Prescriber's Letter 18(3): 2011 CHART: Cytochrome P450 Drug Interactions Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=270307&pb=PRL (subscription needed) http://www.prescribersletter.com

Database